Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 5INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Carcinoma, Non-Small-Cell Lung 481Neoplasms 294Breast Neoplasms 282Colorectal Neoplasms 225Neoplasm Metastasis 191Prostatic Neoplasms 172Ovarian Neoplasms 165Lung Neoplasms 155Multiple Myeloma 153Recurrence 133Melanoma 117Pancreatic Neoplasms 114Squamous Cell Carcinoma of Head and Neck 105Stomach Neoplasms 98Endometrial Neoplasms 98Leukemia, Myeloid, Acute 96Small Cell Lung Carcinoma 85Leukemia, Lymphocytic, Chronic, B-Cell 83Lymphoma, Non-Hodgkin 82Triple Negative Breast Neoplasms 81Carcinoma, Renal Cell 81Carcinoma, Hepatocellular 80Urinary Bladder Neoplasms 75Lymphoma, Large B-Cell, Diffuse 73Lymphoma, Follicular 67Advanced Solid Tumors 64Lymphoma 62Glioblastoma 60Parkinson Disease 4, Autosomal Dominant Lewy Body 56Head and Neck Neoplasms 54

Interventions

belantamab mafodotin 1Dexamethasone 1Cyclophosphamide 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Amyloidosis × 90 days × Clear all
NCT05652335 2026-06-05

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Janssen Research & Development, LLC

Phase 1 Recruiting
180 enrolled
Plasma cell

Amyloidosis, Multiple Myeloma, Recurrence

NCT07081646 2026-03-24

ALACRITY

Alexion Pharmaceuticals, Inc.

Phase 1/2 Recruiting
91 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT07224672 2026-03-17

ALANIS

GlaxoSmithKline

Phase 2 Not yet recruiting
60 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡